A humanized mouse model of HPV-associated pathology driven by E7 expression

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Buitrago Pérez, Águeda ^a   Hachimi, Mariam ^a   Dueñas, Marta ^a   Lloveras, Belén ^b   Santos, Almudena ^c,d   Holguín, Almudena ^a   Duarte, Blanca ^a   Santiago, Juan Luis ^e   Akgül, Baki ^f   Rodríguez Peralto, José L ^g   Storey, Alan ^h   Ribas, Catalina ^c,d   Larcher, Fernando ^a   de Rio, Marcelal ^a   Paramio, Jesús M ^a   García Escudero, Ramón ^a  

^a CIEMAT   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^e UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^f UNIVERSITY OF COLOGNE   (Germany)

^g Universidad Complutense   (Spain)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA 146A; MICRORNA 200A; MICRORNA 21; PROTEIN E7; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ARTIFICIAL SKIN; BOWENOID PAPULOSIS; CELL DIFFERENTIATION; CELL ENGINEERING; CELL PROLIFERATION; CONTROLLED STUDY; E7 GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 5; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MALE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SKIN DEFECT; STABLE EXPRESSION; TUMOR VIRUS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS ONCOGENE; WART VIRUS;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; CYCLIN A; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; EPIDERMIS; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICRORNAS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REPRODUCIBILITY OF RESULTS; RETINOBLASTOMA PROTEIN; SKIN TRANSPLANTATION; TRANSDUCTION, GENETIC; TRANSGENES;

HUMAN PAPILLOMAVIRUS; MUS MUSCULUS;

EID: 84864196455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041743     Document Type: Article

References (79)

1. Akgul B, Cooke JC, Storey A, (2006) HPV-associated skin disease. J Pathol 208: 165-175.
2. Marur S, D'Souza G, Westra WH, Forastiere AA, (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11: 781-789.
3. Pfister H, (2003) Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr pp. 52-56.
4. zur Hausen H, (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92: 690-698.
5. Durst M, Gissmann L, Ikenberg H, zur Hausen H, (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 80: 3812-3815.
6. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11: 1048-1056.
7. Xia H, Cheung WK, Sze J, Lu G, Jiang S, et al. (2010) miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling. J Biol Chem 285: 36995-37004.
8. Viarisio D, Mueller-Decker K, Kloz U, Aengeneyndt B, Kopp-Schneider A, et al. (2011) E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog 7: e1002125.
9. Ramqvist T, Dalianis T, (2011) An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res 31: 1515-1519.
10. Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA, (2010) MicroRNA expression variability in human cervical tissues. PLoS One 5: e11780.
11. Karim R, Meyers C, Backendorf C, Ludigs K, Offringa R, et al. (2011) Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 6: e17848.
12. Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, et al. (2010) Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 16: 1129-1139.
13. Gewirtzman A, Bartlett B, Tyring S, (2008) Epidermodysplasia verruciformis and human papilloma virus. Curr Opin Infect Dis 21: 141-146.
14. Orth G, (2006) Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. Semin Immunol 18: 362-374.
15. de Jong-Tieben LM, Berkhout RJ, ter Schegget J, Vermeer BJ, de Fijter JW, et al. (2000) The prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant recipients with and without a history of skin cancer is equally high: a clinical study to assess risk factors for keratotic skin lesions and skin cancer. Transplantation 69: 44-49.
16. Asgari MM, Kiviat NB, Critchlow CW, Stern JE, Argenyi ZB, et al. (2008) Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 128: 1409-1417.
17. de Koning MN, Weissenborn SJ, Abeni D, Bouwes Bavinck JN, Euvrard S, et al. (2009) Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol 90: 1611-1621.
18. Bouwes Bavinck JN, Neale RE, Abeni D, Euvrard S, Green AC, et al. (2010) Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res 70: 9777-9786.
19. Doorbar J, (2005) The papillomavirus life cycle. J Clin Virol 32: S7-15.
20. Stoler MH, Broker TR, (1986) In situ hybridization detection of human papillomavirus DNAs and messenger RNAs in genital condylomas and a cervical carcinoma. Hum Pathol 17: 1250-1258.
21. McCance DJ, Kopan R, Fuchs E, Laimins LA, (1988) Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci U S A 85: 7169-7173.
22. Dyson N, Howley PM, Munger K, Harlow E, (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934-937.
23. Huibregtse JM, Scheffner M, Howley PM, (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10: 4129-4135.
24. Jones DL, Thompson DA, Munger K, (1997) Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 239: 97-107.
25. Boyer SN, Wazer DE, Band V, (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56: 4620-4624.
26. Gonzalez SL, Stremlau M, He X, Basile JR, Munger K, (2001) Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol 75: 7583-7591.
27. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, et al. (2003) Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 63: 4862-4871.
28. Strati K, Lambert PF, (2007) Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res 67: 11585-11593.
29. Akgul B, Lemme W, Garcia-Escudero R, Storey A, Pfister HJ, (2005) UV-B irradiation stimulates the promoter activity of the high-risk, cutaneous human papillomavirus 5 and 8 in primary keratinocytes. Arch Virol 150: 145-151.
30. Iftner T, Elbel M, Schopp B, Hiller T, Loizou JI, et al. (2002) Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J 21: 4741-4748.
31. Jackson S, Harwood C, Thomas M, Banks L, Storey A, (2000) Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 14: 3065-3073.
32. Jackson S, Storey A, (2000) E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 19: 592-598.
33. Leverrier S, Bergamaschi D, Ghali L, Ola A, Warnes G, et al. (2007) Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria. Apoptosis 12: 549-560.
34. Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA, (2008) E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 82: 10408-10417.
35. Caldeira S, de Villiers EM, Tommasino M, (2000) Human papillomavirus E7 proteins stimulate proliferation independently of their ability to associate with retinoblastoma protein. Oncogene 19: 821-826.
36. Caldeira S, Zehbe I, Accardi R, Malanchi I, Dong W, et al. (2003) The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol 77: 2195-2206.
37. Accardi R, Dong W, Smet A, Cui R, Hautefeuille A, et al. (2006) Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep 7: 334-340.
38. Schaper ID, Marcuzzi GP, Weissenborn SJ, Kasper HU, Dries V, et al. (2005) Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res 65: 1394-1400.
39. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247-1255.
40. Llames SG, Del Rio M, Larcher F, Garcia E, Garcia M, et al. (2004) Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation 77: 350-355.
41. Llames S, GarcÌa E, GarcÌa V, del RÌo M, Larcher F, et al. (2006) Clinical results of an autologous engineered skin. Cell Tissue Bank 7: 47-53.
42. Escamez MJ, Carretero M, GarcÌa M, MartÌnez-SantamarÌa L, Mirones I, et al. (2008) Assessment of optimal virus-mediated growth factor gene delivery for human cutaneous wound healing enhancement. J Invest Dermatol 128: 1565-1575.
43. Escamez MJ, GarcÌa M, Larcher F, Meana A, MuÒoz E, et al. (2004) An in vivo model of wound healing in genetically modified skin-humanized mice. J Invest Dermatol 123: 1182-1191.
44. Di Nunzio F, Maruggi G, Ferrari S, Di Iorio E, Poletti V, et al. (2008) Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors. Mol Ther 16: 1977-1985.
45. Gache Y, Baldeschi C, Del Rio M, Gagnoux-Palacios L, Larcher F, et al. (2004) Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther 15: 921-933.
46. Larcher F, Del Rio M, Serrano F, Segovia JC, Ramirez A, et al. (2001) A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocyte grafts. Faseb J 15: 1529-1538.
47. Rheinwald JG, (1989) Methods for clonal growth and serial cultivation of normal human epidermal keratinocytes and mesothelial cells. In: Baserga R, editors. pp. 81-84 editor. Cell Growth and Division A Practical Approach: IRL Press, Oxford.
48. Meana A, Iglesias J, Del Rio M, Larcher F, Madrigal B, et al. (1998) Large surface of cultured human epithelium obtained on a dermal matrix based on live fibroblast-containing fibrin gels. Burns 24: 621-630.
49. Yang S, Delgado R, King SR, Woffendin C, Barker CS, et al. (1999) Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther 10: 123-132.
50. Del Rio M, Larcher F, Serrano F, Meana A, Munoz M, et al. (2002) A preclinical model for the analysis of genetically modified human skin in vivo. Hum Gene Ther 13: 959-968.
51. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, et al. (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9: 166-180.
52. Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, et al. (2007) Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 67: 4605-4619.
53. Santegoets LA, Seters M, Helmerhorst TJ, Heijmans-Antonissen C, Hanifi-Moghaddam P, et al. (2007) HPV related VIN: highly proliferative and diminished responsiveness to extracellular signals. Int J Cancer 121: 759-766.
54. Martinez-Cruz AB, Santos M, Lara MF, Segrelles C, Ruiz S, et al. (2008) Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res 68: 683-692.
55. Segrelles C, Lu J, Hammann B, Santos M, Moral M, et al. (2007) Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis. Cancer Res 67: 10879-10888.
56. Ruiz S, Santos M, Segrelles C, Leis H, Jorcano JL, et al. (2004) Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 131: 2737-2748.
57. Schmitt A, Harry JB, Rapp B, Wettstein FO, Iftner T, (1994) Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. J Virol 68: 7051-7059.
58. Yamashita T, Segawa K, Fujinaga Y, Nishikawa T, Fujinaga K, (1993) Biological and biochemical activity of E7 genes of the cutaneous human papillomavirus type 5 and 8. Oncogene 8: 2433-2441.
59. Crum CP, Ikenberg H, Richart RM, Gissman L, (1984) Human papillomavirus type 16 and early cervical neoplasia. N Engl J Med 310: 880-883.
60. Dubina M, Goldenberg G, (2009) Viral-associated nonmelanoma skin cancers: a review. Am J Dermatopathol 31: 561-573.
61. Jian Y, Schmidt-Grimminger DC, Chien WM, Wu X, Broker TR, et al. (1998) Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes. Oncogene 17: 2027-2038.
62. Ruesch MN, Laimins LA, (1998) Human papillomavirus oncoproteins alter differentiation-dependent cell cycle exit on suspension in semisolid medium. Virology 250: 19-29.
63. Zehbe I, Ratsch A, Alunni-Fabbroni M, Burzlaff A, Bakos E, et al. (1999) Overriding of cyclin-dependent kinase inhibitors by high and low risk human papillomavirus types: evidence for an in vivo role in cervical lesions. Oncogene 18: 2201-2211.
64. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, et al. (2009) Apoptosis and cancer: mutations within caspase genes. J Med Genet 46: 497-510.
65. Moody CA, Fradet-Turcotte A, Archambault J, Laimins LA, (2007) Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc Natl Acad Sci U S A 104: 19541-19546.
66. Middleton K, Peh W, Southern S, Griffin H, Sotlar K, et al. (2003) Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 77: 10186-10201.
67. Buitrago-Perez A, Garaulet G, Vazquez-Carballo A, Paramio JM, Garcia-Escudero R, (2009) Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling. Curr Genomics 10: 26-34.
68. Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ, et al. (2008) Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res 14: 2535-2542.
69. Lui WO, Pourmand N, Patterson BK, Fire A, (2007) Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 67: 6031-6043.
70. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, et al. (2008) Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 27: 2575-2582.
71. Wang X, Tang S, Le SY, Lu R, Rader JS, et al. (2008) Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 3: e2557.
72. Selcuklu SD, Donoghue MT, Spillane C, (2009) miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 37: 918-925.
73. Azuma M, Ritprajak P, Hashiguchi M, (2010) Topical application of siRNA targeting cutaneous dendritic cells in allergic skin disease. Methods Mol Biol 623: 373-381.
74. Taganov KD, Boldin MP, Chang KJ, Baltimore D, (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 103: 12481-12486.
75. Sonkoly E, Stahle M, Pivarcsi A, (2008) MicroRNAs: novel regulators in skin inflammation. Clin Exp Dermatol 33: 312-315.
76. Saydam O, Shen Y, Wurdinger T, Senol O, Boke E, et al. (2009) Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 29: 5923-5940.
77. Funk JO, Waga S, Harry JB, Espling E, Stillman B, et al. (1997) Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11: 2090-2100.
78. Helt AM, Funk JO, Galloway DA, (2002) Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J Virol 76: 10559-10568.
79. Jones DL, Alani RM, Munger K, (1997) The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 11: 2101-2111.